Update
$Soligenix (SNGX.US)$ Soligenix Plans To Initiate Patient Enrollment In The Confirmatory FLASH 2 Study With HyBryte By The End Of 2024; Continues To Explore The Potential Of HyBryte In Treating Other Dermatological Conditions Such As Psoriasis
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
